Print

NanoSmart Pharmaceuticals, Inc. to Present as Top Innovator Company at New England Venture Summit, December 5  
12/4/2012 10:36:27 AM

LAGUNA HILLS, Calif., Dec. 3, 2012 /PRNewswire/ -- Dr. James Smith, President of NanoSmart Pharmaceuticals, has been selected as a Top Innovator to present at the New England Venture Summit on Wednesday, December 5 in Boston, MA. Dr. Smith will discuss NanoSmart Pharmaceuticals' novel drug-delivery platform utilizing a human-derived antinuclear antibody that targets areas of necrosis present in all solid tumors. The presentation will include current status and planned development milestones, while explaining the benefits of reformulating existing drugs using NanoSmart's tumor targeting platform.

"There is a need for new and more-effective therapeutic products across all types of cancers; but particularly for those rare cancers that are often overlooked and/or underserved," said Dr. Smith. "We are pleased with the progress we are making in developing our pipeline and the success of our initial preclinical studies. Our ability to non-specifically target cancer tumors affords us the opportunity to rapidly commercialize new treatments for a wide range of pediatric/orphan indications."

Upon conclusion, details from the presentation and additional materials will be made available by request.

ABOUT NanoSmart Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc.,a private biotechnology company, is developing novel proprietary drug delivery products to treat cancer and other serious life threatening diseases. NanoSmart's patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of cancer and other diseases. NanoSmart has completed development of its preliminary immunoliposomal formulations and is currently engaged in preclinical testing of its lead candidate drug products.

This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.

SOURCE NanoSmart Pharmaceuticals, Inc.


//-->